As with most supplements, the limited studies are incredibly encouraging, but finding funding is difficult
You respond well at lower doses
S., & Zizzi, S
(5) R C Rosen, L E Diamond, D C Earle, et al (2004) Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra International Journal of Impotence Research, volume 16, pages 135142 (2004)
Further, those with larger, palpable fibroids will likely know if an intervention is effective or not themselves
If we consider that around one in eight Americans have already tried a GLP-1 drug, according to healthy policy organisation KFF, and that more than two in five adults in the US live with obesity, there is real opportunity for pharma companies to meet this demand